Two Bills, One Senate Calendar: Where Marrow Reauthorization Stands

When the House passed H.R. 5160 in July, we wrote that the vote was consequential but not final. Five weeks later, that is still the accurate description, and the situation has become easier to state precisely.

The record, in order

According to the official bill status record:

• June 17 — the Senate Committee on Health, Education, Labor and Pensions advanced S. 4109 unanimously.
• June 22 — S. 4109 was placed on the Senate Legislative Calendar under General Orders, Calendar No. 443.
• July 2 — the House Committee on Energy and Commerce reported H.R. 5160 as amended, H. Rept. 119-724.
• July 20 — the House considered the bill under suspension of the rules, held forty minutes of debate, and passed it as amended by voice vote.
• July 21 — the bill was received in the Senate, read twice, and placed on the Senate Legislative Calendar under General Orders, Calendar No. 464.

So both measures are now on the same calendar. Neither has received floor time.

Two details are worth flagging because they get reported loosely. The House vote was July 20, not July 21 — July 21 is when advocacy organizations issued their statements. And because it passed by voice vote under suspension of the rules, there is no roll call. Nobody's individual vote was recorded, so no member can accurately be described as having voted for or against it.

What the bills would do

Both would reauthorize the C.W. Bill Young Cell Transplantation Program and the National Cord Blood Inventory through fiscal year 2031 — the federal architecture that connects transplant centers, volunteer donors, cord blood banks and patient support services.

The Senate-reported text and the House-passed text are closely related but not identical. The Senate version would restart and broaden the existing biennial state-of-the-science review, extending its scope to high-quality cord blood units and emerging technologies, and would direct the secretary to consult the Advisory Council on Blood Stem Cell Transplantation on managing the cord blood inventory.

That difference matters procedurally. Both chambers must pass identical text before anything reaches the president.

Authorization is not money

This is the distinction most coverage blurs. Reauthorization sets the ceiling — it grants permission for a program to exist and to be funded at a stated level, here roughly $165 million over five years. Appropriations supply the actual money, in a separate process, every year.

A reauthorized program that never gets appropriated is a program on paper. Passing these bills is necessary. It is not sufficient.

What happens next

The Senate has to act. If it passes text different from the House version, the chambers have to resolve the difference and pass the same language. Only then can an enrolled bill go to the president.

There is no deadline forcing this, which is precisely why bills sit on calendars. In the meantime the program continues to operate — in the first quarter of fiscal 2026 alone it facilitated more than 4,400 unrelated transplants, over 3,800 of them for patients in the United States.

We will update this page when the Senate acts.